H.C. Wainwright lowered the firm’s price target on Avalo Therapeutics (AVTX) to $35 from $40 and keeps a Buy rating on the shares. The LOTUS results showed that abdakibart is active in hidradenitis suppurativa, but did not definitively displace AbbVie’s (ABBV) lutikizumab on HiSCR75 depth or placebo-adjusted separation, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics price target lowered to $55 from $62 at Citizens
- Avalo Therapeutics Urges Investors to Heed Form 10-Q Risk Factors Amid Ongoing Uncertainty
- Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)
- Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler
- Avalo Therapeutics Announces Major Equity and Warrant Offering